Compare DLTH & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | MDWD |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7M | 162.2M |
| IPO Year | 2015 | 2013 |
| Metric | DLTH | MDWD |
|---|---|---|
| Price | $4.37 | $13.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.00 | ★ $30.67 |
| AVG Volume (30 Days) | 55.7K | ★ 90.6K |
| Earning Date | 12-15-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $565,184,000.00 | N/A |
| Revenue This Year | N/A | $39.60 |
| Revenue Next Year | $3.12 | $34.34 |
| P/E Ratio | $19.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $11.80 |
| 52 Week High | $5.09 | $19.70 |
| Indicator | DLTH | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 56.96 |
| Support Level | $3.82 | $12.76 |
| Resistance Level | $4.77 | $14.06 |
| Average True Range (ATR) | 0.15 | 0.54 |
| MACD | 0.05 | 0.20 |
| Stochastic Oscillator | 86.51 | 75.34 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.